https://www.myneotx.com/2026-09-02monthly1.0 https://www.myneotx.com/solutions2026-09-02monthly0.9 https://www.myneotx.com/solutions/mysurface2026-09-02monthly0.8 https://www.myneotx.com/solutions/myada2026-09-02monthly0.8 https://www.myneotx.com/solutions/myself2026-09-02monthly0.8 https://www.myneotx.com/solutions/myinsights2026-09-02monthly0.8 https://www.myneotx.com/solutions/myneo2026-09-02monthly0.8 https://www.myneotx.com/solutions/myshared2026-09-02monthly0.8 https://www.myneotx.com/solutions/mypathogen2026-09-02monthly0.8 https://www.myneotx.com/solutions/myepitope2026-09-02monthly0.8 https://www.myneotx.com/solutions/myconstruct2026-09-02monthly0.8 https://www.myneotx.com/solutions/myrna2026-09-02monthly0.8 https://www.myneotx.com/platform2026-09-02monthly0.9 https://www.myneotx.com/platform/immunoengine2026-09-02monthly0.9 https://www.myneotx.com/platform/neoms2026-09-02monthly0.9 https://www.myneotx.com/platform/neoim2026-09-02monthly0.9 https://www.myneotx.com/platform/camyotopes2026-09-02monthly0.9 https://www.myneotx.com/publications2026-09-02weekly0.8 https://www.myneotx.com/assets2026-09-02monthly0.7 https://www.myneotx.com/assets/mne-c2612026-09-02monthly0.6 https://www.myneotx.com/about-us2026-09-02monthly0.6 https://www.myneotx.com/news-events2026-09-02weekly0.7 https://www.myneotx.com/careers2026-09-02weekly0.6 https://www.myneotx.com/contact2026-09-02yearly0.5 https://www.myneotx.com/faq2026-09-02weekly0.8 https://www.myneotx.com/how-we-differ2026-09-02monthly0.9 https://www.myneotx.com/about-us/team/bert-coessens-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/bruno-fant-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/cedric-bogaert2026-09-02monthly0.6 https://www.myneotx.com/about-us/advisors/em-prof-kris-thielemans-phd-md2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/emiel-evenepoel2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/gitta-boons-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/board/jan-van-den-berghe2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/jens-de-ceukeleire2026-09-02monthly0.6 https://www.myneotx.com/about-us/advisors/john-castle-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/lena-pfitzer2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/lien-lybaert-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/lore-van-oudenhove2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/manon-montyne2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/marie-van-hecke-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/board/mark-vaeck2026-09-02monthly0.6 https://www.myneotx.com/about-us/advisors/patrick-ott-phd-md2026-09-02monthly0.6 https://www.myneotx.com/about-us/advisors/prof-timon-vandamme-phd-md2026-09-02monthly0.6 https://www.myneotx.com/about-us/board/prof-wim-van-criekinge-phd2026-09-02monthly0.6 https://www.myneotx.com/about-us/team/sofie-pontzeele2026-09-02monthly0.6 https://www.myneotx.com/post/myneo-therapeutics-supports-first-patient-dosing-in-the-neovacc-phase-i-trial2026-08-01yearly0.5 https://www.myneotx.com/post/a-vib-ku-leuven-collaboration-to-advance-novel-breast-cancer-therapies2026-06-30yearly0.5 https://www.myneotx.com/post/releases-immunoengine-neohub2026-06-02yearly0.5 https://www.myneotx.com/post/immunology-leader2026-05-29yearly0.5 https://www.myneotx.com/post/myneo-part-of-three-multidisciplinary-collaborative-research-programs2026-04-28yearly0.5 https://www.myneotx.com/post/strategic-collaboration-with-vib-ccb2026-01-19yearly0.5 https://www.myneotx.com/post/new-publication-neoim-a-predictive-model-for-neoantigen-immunogenicity2025-09-22yearly0.5 https://www.myneotx.com/post/european-patent-office-further-protects-myneos-ip-position-and-computational-platform2025-06-11yearly0.5 https://www.myneotx.com/post/myneo-therapeutics-partners-with-curevac2025-04-13yearly0.5 https://www.myneotx.com/post/the-launch-of-neohub2025-02-18yearly0.5 https://www.myneotx.com/post/bloovi-interview2025-02-14yearly0.5 https://www.myneotx.com/post/review-trend-in-cancer-challenges-in-neoantigen-directed-therapeutics2025-01-29yearly0.5 https://www.myneotx.com/post/press-release-with-university-of-liverpool2025-01-21yearly0.5 https://www.myneotx.com/post/odimma-partners-with-myneo-therapeutics-for-the-clinical-development-of-its-personalized-dna-based-cancer-immunotherapy2025-01-14yearly0.5 https://www.myneotx.com/post/myneo-therapeutics-invited-as-speaker-for-a-webinar-about-immunotherapy-organized-by-lvv-a-cancer-patient-organization2025-01-09yearly0.5 https://www.myneotx.com/post/review-publication-in-cancer-cell2024-12-19yearly0.5 https://www.myneotx.com/post/antigen-target-library2024-12-03yearly0.5 https://www.myneotx.com/post/camyo-01-update2024-12-03yearly0.5 https://www.myneotx.com/post/camyo-02-update2024-09-15yearly0.5 https://www.myneotx.com/post/sob-case-study2024-05-29yearly0.5 https://www.myneotx.com/post/curevac-exercises-options-in-strategic-collaboration-with-myneo-therapeutics2023-11-21yearly0.5 https://www.myneotx.com/post/myneo-therapeutics-ceo-cedric-bogaert-receives-medical-genetics-award-at-the-vatican2023-11-15yearly0.5 https://www.myneotx.com/post/myneo-evolves-into-myneo-therapeutics2023-10-24yearly0.5 https://www.myneotx.com/post/hookipa-hpv-case-study2023-10-16yearly0.5 https://www.myneotx.com/post/cedric-bogaert-selected-in-the-forbes-30under30-europe-list-20232023-03-31yearly0.5 https://www.myneotx.com/post/myneo-therapeutics-has-won-the-2022-most-disruptive-innovator-award2022-11-13yearly0.5 https://www.myneotx.com/post/curevac-partners-with-myneo-therapeutics-to-identify-novel-antigen-targets-for-mrna-based-cancer-vaccine-development2022-05-24yearly0.5 https://www.myneotx.com/publication/myada-anti-drug-antibody-risk-prediction2026-09-02monthly0.6 https://www.myneotx.com/publication/myepitope-immunogenicity-prediction2026-09-02monthly0.6 https://www.myneotx.com/publication/myconstruct-string-of-beads-optimization2026-09-02monthly0.6 https://www.myneotx.com/publication/myself-immunogenicity-autoimmune-disease2026-09-02monthly0.6 https://www.myneotx.com/publication/pfitzer-accelerating-neoantigen-discovery-20252025-08-15monthly0.6 https://www.myneotx.com/publication/godazandeh-methods-neoantigen-prediction-20232023-01-01monthly0.6 https://www.myneotx.com/publication/lybaert-neoantigen-therapeutics-clinic-20232023-04-11monthly0.6 https://www.myneotx.com/publication/lybaert-challenges-neoantigen-therapeutics-20222022-10-01monthly0.6 https://www.myneotx.com/publication/mill-neoms-mhc-epitope-presentation-20222022-05-13monthly0.6 https://www.myneotx.com/publication/de-mey-innate-immune-agonist-mrna-20222022-09-01monthly0.6 https://www.myneotx.com/publication/case-study-personalized-vaccine-development2026-09-02monthly0.6 https://www.myneotx.com/publication/camyotopes-novel-class-tumor-targets2026-09-02monthly0.6 https://www.myneotx.com/publication/more-to-genome-wgs-neoantigen-discovery2026-09-02monthly0.6 https://www.myneotx.com/publication/simulated-sequencing-data-benchmarking2026-09-02monthly0.6 https://www.myneotx.com/publication/optimal-neoantigen-prediction-sweet-spot2026-09-02monthly0.6 https://www.myneotx.com/publication/liquid-biopsies-personalized-medicine2026-09-02monthly0.6 https://www.myneotx.com/publication/beyond-snvs-indels-neoantigen-prediction2026-09-02monthly0.6 https://www.myneotx.com/publication/transposable-elements-cancer2026-09-02monthly0.6 https://www.myneotx.com/publication/gut-microbiome-cancer-immunotherapy2026-09-02monthly0.6 https://www.myneotx.com/publication/promise-personalized-cancer-vaccination2026-09-02monthly0.6 https://www.myneotx.com/publication/immunotherapy-holy-grail-fight-against-cancer2026-09-02monthly0.6 https://www.myneotx.com/publication/immunosurveillance-cd4-t-cells-cancer2026-09-02monthly0.6 https://www.myneotx.com/publication/ferroptosis-armed-dendritic-cell-vaccines-for-glioma-immunotherapy2026-05-07monthly0.6